Cross-Sector entity
Of the tracked stories, 1 of 2 also mention Benchmark, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 160-day span. ipo accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder.
2 verified stories tracked
Last mentioned: Aug 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention Benchmark, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 160-day span. ipo accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Dexcom appears in 2 tracked Cross-Sector stories published from March 6, 2026 through August 12, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dexcom. Shared-story counts are live from our verified record — not editorial picks.
Benchmark boosted outlooks on two disparate stocks—First Internet Bancorp and DexCom—offering a stark contrast in risk/reward. While INBK promises 21.74% upside based on the new $35 target, DXCM’s $82 target sits slightly below its trading price, highlighting valuation concerns despite a Buy rating.
Source: dailypolitical.com · themarketsdaily.com
Medtronic plc has priced the initial public offering of its diabetes-focused subsidiary, MiniMed Group Inc., at $20.00 per share for 28 million shares. The $560 million carve-out aims to provide the specialized unit with independent capital to compete in the high-growth insulin delivery and monitoring market.
